Repository logo
 

The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.

Published version
Peer-reviewed

Repository DOI


Loading...
Thumbnail Image

Type

Article

Change log

Authors

Meek, Claire L 
Lewis, Hannah B 
Gribble, Fiona M 
Park, Adrian J 

Abstract

Bariatric surgery for obesity has proved to be an extremely effective method of promoting long-term weight reduction with additional beneficial metabolic effects, such as improved glucose tolerance and remission of type 2 diabetes. A range of bariatric procedures are in common use, including gastric banding, sleeve gastrectomy and the Roux-en-Y gastric bypass. Although the mechanisms underlying the efficacy of bariatric surgery are unclear, gastrointestinal and pancreatic peptides are thought to play an important role. The aim of this review is to summarise the effects of different bariatric surgery procedures upon gastrointestinal and pancreatic peptides, including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic hormone (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin, insulin, glucagon and somatostatin.

Description

Keywords

Bariatric, Cholecystokinin, Gastrin, Ghrelin, Incretin, Oxyntomodulin, Animals, Appetite, Bariatric Surgery, Gastrointestinal Hormones, Gastrointestinal Tract, Humans, Obesity, Pancreas, Pancreatic Hormones

Journal Title

Peptides

Conference Name

Journal ISSN

0196-9781
1873-5169

Volume Title

77

Publisher

Elsevier BV
Sponsorship
Medical Research Council (MC_UU_12012/3)
Medical Research Council (MC_PC_12012)
Research in the F. Reimann and F.M. Gribble laboratories is funded by the Wellcome Trust (WT084210Z/07/Z and WT088357Z/09/Z), the MRC (MRC_MC_UU_12012/3) and Full4Health (FP7/2011-2015, grant agreement no. 266408). Claire Meek receives additional salary funding from the Wellcome Trust Translational Medicine and Therapeutics Programme, funded by the Wellcome Trust in association with Glaxo SmithKline.